Humacyte HUMA

NASDAQ HUMA

$0.57 -0.01 (-2.31%)

As of: Sep 10, 2026 · 9:53 AM EDT

Key Stats

Market Cap133.16 Mn

P/E-1.11

P/S62.78

Div. Yield0.00

Total Debt (Qtr)36.32 Mn

Add ratio to table…

About

Humacyte, Inc. is a commercial stage biotechnology platform company that develops universally implantable, bioengineered human tissues at commercial scale. The company’s lead product is Symvess, an acellular tissue engineered vessel approved by the FDA in December 2024 for use as a vascular conduit in extremity arterial injury when autologous vein graft is not feasible. Beyond vascular trauma, Humacyte is advancing a pipeline that includes vessels for hemodialysis access, peripheral artery disease, coronary artery bypass grafting, pediatric heart surgery and delivery of pancreatic islet cells for Type 1 diabetes. The firm manufactures its products in an 83,000 square foot facility in Durham, North Carolina using a modular LUNA200 system that can produce up to 200 vessels per batch. As of December 31, 2025, approximately 636 patients had received the company’s vessels in clinical trials and additional patients have been treated following the commercial launch of Symvess in the first quarter of 2025.

Humacyte generates revenue primarily from the sale of its FDA approved product Symvess to hospitals and medical facilities. The company also receives revenue sharing and fees from its distribution agreement with Fresenius Medical Care for markets outside the United States and the European Union. Future revenue is expected from the commercialization of additional product candidates such as vessels for arteriovenous access in dialysis, peripheral artery bypass and pancreatic islet delivery. The firm may also earn royalties from licensing its technology to third parties under existing agreements with academic institutions. Overall, the business model relies on product sales, partnership income and potential licensing proceeds.

Humacyte occupies a niche in the regenerative medicine market where it offers off the shelf, universally implantable vessels that avoid immune rejection and have demonstrated low infection rates in clinical trials. The company’s products are designed to be immediately available without the need for harvesting autologous veins, which reduces procedure time and associated complications. Key competitors include established providers of synthetic grafts such as Bard Peripheral Vascular, W. L. Gore & Associates, Terumo Medical Systems and Atrium (Maquet Getinge). Humacyte’s competitive advantages stem from its proprietary manufacturing process that yields uniform, predictable tissue quality and from the ability of its vessels to remodel with host cells after implantation, potentially providing long term durability. The firm also benefits from a strong intellectual property portfolio that includes fifteen families of patents covering scaffolds, composition and manufacturing methods.

Humacyte serves hospitals, trauma centers, outpatient surgical centers and dialysis clinics that require vascular conduits for trauma repair, hemodialysis access and peripheral artery bypass. Specific partners include Fresenius Medical Care, which holds distribution rights for the company’s products outside the United States and the European Union. The firm also works with academic medical centers and research hospitals that have participated in its clinical trials across the United States, Europe and Asia. In addition, the company has supplied vessels to military and humanitarian programs, including a collaboration with the Department of Defense for vascular trauma treatment and a program that provided implants to surgeons in Ukraine during conflict.

Investment Thesis

▲ Bull case

Humacyte's commercial launch of Symvess for extremity vascular trauma is gaining significant traction, with 45 Level 1 trauma centers already in the VAC approval process and five hospitals having already approved purchases, indicating strong early adoption despite economic headwinds and negative press. The company's budget impact model published in the Journal of Medical Economics demonstrates clear cost savings by reducing conduit infections and limb amputations compared to synthetic conduits and xenografts, providing a compelling value proposition that is resonating with hospital value analysis committees and surgeons. This economic argument, combined with ongoing surgeon training and positive clinical experiences, is overcoming initial skepticism and building momentum for broader formulary inclusion, which positions Symvess for accelerated uptake in the second half of 2025 as management anticipates. The ATEV pipeline for dialysis access represents a substantial near-term catalyst, with the V012 Phase 3 trial having enrolled 84 of 150 patients and on track for an interim analysis in April 2026 when the first 80 patients reach 12-month follow-up, enabling a planned supplemental BLA filing in the second half of 2026. This is bolstered by the successful V007 trial, which met primary endpoints showing superior patency at six and 12 months versus autogenous fistula and identified high-risk subgroups (women, diabetic, obese patients) comprising over half the dialysis market where standard of care fails approximately 50% of the time, creating a clear target population with high unmet need. Fresenius's continued partnership and alignment with reimbursement shifts that penalize centers for excessive catheter use further validate the clinical and economic rationale for ATEV in dialysis, reducing commercialization risk. The planned IND filing for the small-diameter ATEV (3.5mm) in coronary artery bypass grafting (CABG) later in 2025 opens a multi-billion dollar peripheral and coronary artery disease market beyond the current trauma and dialysis indications, leveraging the same core technology with de-risked manufacturing processes from the approved Symvess product. Management's recent FDA meeting supports this IND filing, and initiating first-in-human trials would represent a major valuation inflection point, especially as the 6mm ATEV has already demonstrated safety and efficacy in human trials for trauma, dialysis, and peripheral arterial disease, providing a strong foundation for scaling to smaller diameters in new indications.

Humacyte's commercial launch of Symvess for extremity vascular trauma is gaining significant traction, with 45 Level 1 trauma centers already in the VAC approval process and five hospitals having already approved purchases, indicating strong early adoption despite economic headwinds and negative press. The company's budget impact model published in the Journal of Medical Economics demonstrates clear cost savings by reducing conduit infections and limb amputations compared to synthetic conduits and xenografts, providing a compelling value proposition that is resonating with hospital value analysis committees and surgeons. This economic argument, combined with ongoing surgeon training and positive clinical experiences, is overcoming initial skepticism and building momentum for broader formulary inclusion, which positions Symvess for accelerated uptake in the second half of 2025 as management anticipates. The ATEV pipeline for dialysis access represents a substantial near-term catalyst, with the V012 Phase 3 trial having enrolled 84 of 150 patients and on track for an interim analysis in April 2026 when the first 80 patients reach 12-month follow-up, enabling a planned supplemental BLA filing in the second half of 2026. This is bolstered by the successful V007 trial, which met primary endpoints showing superior patency at six and 12 months versus autogenous fistula and identified high-risk subgroups (women, diabetic, obese patients) comprising over half the dialysis market where standard of care fails approximately 50% of the time, creating a clear target population with high unmet need. Fresenius's continued partnership and alignment with reimbursement shifts that penalize centers for excessive catheter use further validate the clinical and economic rationale for ATEV in dialysis, reducing commercialization risk. The planned IND filing for the small-diameter ATEV (3.5mm) in coronary artery bypass grafting (CABG) later in 2025 opens a multi-billion dollar peripheral and coronary artery disease market beyond the current trauma and dialysis indications, leveraging the same core technology with de-risked manufacturing processes from the approved Symvess product. Management's recent FDA meeting supports this IND filing, and initiating first-in-human trials would represent a major valuation inflection point, especially as the 6mm ATEV has already demonstrated safety and efficacy in human trials for trauma, dialysis, and peripheral arterial disease, providing a strong foundation for scaling to smaller diameters in new indications.

▼ Bear case

Humacyte's Symvess commercial launch faces significant headwinds from unfounded negative press, exemplified by the New York Times article cited by management during the Q&A, which created VAC pushback and delayed hospital adoption despite clinical validity, indicating vulnerability to reputational risks that could persist or recur and undermine physician confidence even as long-term data emerges. The company's reliance on surgeon champions and VAC approvals—a process explicitly described as taking three to six months for the majority of submissions—means revenue recognition remains heavily back-loaded, with most 2025 sales expected in the second half, leaving near-term financial performance highly dependent on execution in a turbulent economic environment where hospitals are scrutinizing all new product costs. The V012 dialysis access trial, while progressing with 84 patients enrolled, remains a small Phase 3 study of only 150 patients, and its interim analysis in April 2026 is contingent on the first 80 patients reaching 12-month follow-up, introducing timing risk if enrollment slows or follow-up is delayed; furthermore, the supplemental BLA filing planned for late 2026 depends on combining V012 data with the V007 trial, but any negative or inconclusive interim results could jeopardize the filing timeline and raise doubts about the ATEV's efficacy in the target subgroups, particularly given the complexity of the dialysis patient population and variability in real-world conduit handling by dialysis centers and interventionists that management acknowledged they are closely monitoring. Cost-saving measures implemented after the March 2025 financing, including a 31-employee workforce reduction and deferred hiring, while extending cash runway, risk undermining critical commercial and R&D momentum—especially the sales force's ability to support military hospital penetration via ECAT and sustain surgeon advocacy across 200+ Level 1 trauma centers—since management admitted the current sales force is only "comfortable" covering existing geographies and would need expansion only after increased success, creating a potential bottleneck in scaling adoption just as VAC approvals begin to convert to orders, and the one-time $800,000 severance charge suggests the cuts were deeper than optimal for sustaining multi-indication commercial launches.

Humacyte's Symvess commercial launch faces significant headwinds from unfounded negative press, exemplified by the New York Times article cited by management during the Q&A, which created VAC pushback and delayed hospital adoption despite clinical validity, indicating vulnerability to reputational risks that could persist or recur and undermine physician confidence even as long-term data emerges. The company's reliance on surgeon champions and VAC approvals—a process explicitly described as taking three to six months for the majority of submissions—means revenue recognition remains heavily back-loaded, with most 2025 sales expected in the second half, leaving near-term financial performance highly dependent on execution in a turbulent economic environment where hospitals are scrutinizing all new product costs. The V012 dialysis access trial, while progressing with 84 patients enrolled, remains a small Phase 3 study of only 150 patients, and its interim analysis in April 2026 is contingent on the first 80 patients reaching 12-month follow-up, introducing timing risk if enrollment slows or follow-up is delayed; furthermore, the supplemental BLA filing planned for late 2026 depends on combining V012 data with the V007 trial, but any negative or inconclusive interim results could jeopardize the filing timeline and raise doubts about the ATEV's efficacy in the target subgroups, particularly given the complexity of the dialysis patient population and variability in real-world conduit handling by dialysis centers and interventionists that management acknowledged they are closely monitoring. Cost-saving measures implemented after the March 2025 financing, including a 31-employee workforce reduction and deferred hiring, while extending cash runway, risk undermining critical commercial and R&D momentum—especially the sales force's ability to support military hospital penetration via ECAT and sustain surgeon advocacy across 200+ Level 1 trauma centers—since management admitted the current sales force is only "comfortable" covering existing geographies and would need expansion only after increased success, creating a potential bottleneck in scaling adoption just as VAC approvals begin to convert to orders, and the one-time $800,000 severance charge suggests the cuts were deeper than optimal for sustaining multi-indication commercial launches.

Product and Service Breakdown of Revenue (2025)

Peer group

Peer Comparison

Companies in the Gene and Cell Therapy

S.No.	Ticker	Company	match	Market Cap	P/E	P/S	Total Debt (Qtr)
1	KRYS	Krystal Biotech, Inc.	primary	10.26 Bn	42.49	23.29	-
2	CRSP	CRISPR Therapeutics AG	primary	5.02 Bn	-10.38	375.08	586.20 Mn
3	IOVA	Iovance Biotherapeutics, Inc.	primary	3.73 Bn	-17.86	11.49	-
4	LEGN	Legend Biotech Corp	primary	3.62 Bn	-171.92	2.85	156.40 Mn
5	QURE	uniQure N.V.	primary	2.99 Bn	-15.21	160.22	50.15 Mn
6	BEAM	Beam Therapeutics Inc.	primary	2.52 Bn	-29.52	16.16	112.43 Mn
7	PGEN	Precigen, Inc.	primary	2.36 Bn	-7.02	27.56	93.88 Mn
8	SRPT	Sarepta Therapeutics, Inc.	primary	2.25 Bn	-16.41	1.14	847.62 Mn

Humacyte HUMA

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password